Morgan Stanley Downgrades Merck (MRK) to Underweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Leerink Swann Downgrades Merck (MRK) to Market Perform
February 4, 2013 7:20 AM ESTLeerink Swann downgraded Merck (NYSE: MRK) from Outperform to Market Perform.
The firm cited: "(1) reduced prospects with the delay/uncertainty around odanacatib, (2) increasing 2013+ competition vs. Januvia & Isentress as well as the outcome of Germany's (G-BA/AMNOG) planned assessment of DPP-IV inhibitors, (3) ongoing investor... More
